BioNTech launches first human test of BNT317 against advanced cancers

NCT ID NCT06750185

Recruiting now Disease control Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if BNT317 will actually fight cancer, but this study is a necessary first step.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BNT317 (an experimental biologic drug given by intravenous infusion)
What this could lead to: If this early trial shows BNT317 is safe and tolerable, it could pave the way for larger studies to see if it helps shrink or control advanced solid tumors.
What could go wrong: This is a very early, first-in-human study with only 39 people, so the main goal is safety, not effectiveness. Many promising drugs fail in later stages, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Cancer Research SA
RECRUITING

Adelaide, 5000, Australia
Carolina BioOncology Institute, LLC
RECRUITING

Huntersville, North Carolina, 28078, United States
MUSC Hollings Cancer Center
RECRUITING

Charleston, South Carolina, 29425, United States
Mary Crowley Cancer Research
RECRUITING

Dallas, Texas, 75230, United States
Monash Medical Centre Clayton
RECRUITING

Clayton, 3168, Australia
Norton Cancer Institute PARENT
RECRUITING

Louisville, Kentucky, 40202, United States
Rhode Island Hospital
RECRUITING

East Providence, Rhode Island, 02903, United States
START Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
Scientia Clinical Research
RECRUITING

Randwick, 2031, Australia
South Texas Accelerated Research Therapeutics (START), LLC
RECRUITING

San Antonio, Texas, 78229, United States
Tasman Oncology Research Ltd
RECRUITING

Southport, Queensland, 4215, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.